Study: NCT01809184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 287
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 287
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 287
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 287
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 287
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 287
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 287
Description: Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo adminstered corresponding to insulin 287 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo adminstered corresponding to insulin 287 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo adminstered corresponding to insulin 287 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo adminstered corresponding to insulin 287 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo adminstered corresponding to insulin 287 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo adminstered corresponding to insulin 287 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral placebo adminstered corresponding to insulin 287 treatment